Key Highlights
- Baird Medical Investment Holdings Limited (NASDAQ:BDMD) traded up 20.26% to USD 0.1312 in trading on November 5, 2026, per published market data, with about 108.64 million shares changing hands.
- Nasdaq sent a minimum bid price deficiency letter dated November 2, 2026, announced by the company on November 4, 2026.
- The company has 180 calendar days, until May 3, 2027, to restore a closing bid of USD 1.00 for at least ten consecutive Business days.
- On November 4, 2026 the company said it knew of no material development or undisclosed reason behind its recent share price decline.
Nasdaq Deficiency Notice and Company Statement
Baird Medical announced on November 4, 2026 that it received a Nasdaq letter dated November 2, 2026 under Listing Rule 5550(a)(2), because its bid price had stayed below USD 1.00 for 30 consecutive business days. The deficiency has no immediate effect on trading. The company has 180 calendar days, until May 3, 2027, to regain compliance, which requires a closing bid of at least USD 1.00 for ten consecutive business days. A second 180-day period may be available if it meets other listing standards and gives written notice of its intent to cure. Management said it is looking into various options. A separate statement on November 4, 2026 said the company was monitoring its share price and trading and knew of no undisclosed reason for the decline.
Business Background and Compliance Mechanics
Baird Medical describes itself as a medical device company focused on minimally invasive microwave ablation. Its lead system is cleared by the United States Food and Drug Administration for soft tissue ablation and is being introduced in the United States mainly for benign thyroid nodules. The company is also developing products based on irreversible electroporation and an artificial intelligence guided robotic ablation system. The usual cures for a bid price deficiency are a reverse stock split, which cuts the share count and lifts the quoted price without changing the company's value, or a sustained recovery in the price itself. The notice did not mention a reverse split, and none is confirmed. Published market data lists trailing diluted EPS of negative USD 0.55.
Risks and What to Watch
At USD 0.1312 and a published market Capitalization near USD 4.2 million, Baird Medical is a nano-cap name. The price sits far below the USD 1.00 threshold, so a recovery without a reverse split would require a gain of more than sevenfold, simple arithmetic on the two published numbers. A small number of trades can move the price, spreads can be wide and quoted moves can reverse. Volume of about 108.64 million shares is roughly five times the average, which signals heavy speculative turnover rather than a change in fundamentals. A reverse split, financing that dilutes holders or a failure to cure by May 3, 2027 could each follow. Watch for company filings on a compliance plan and any Shareholder approval.
Where Things Stand
The spike at Baird Medical Investment Holdings Limited (NASDAQ:BDMD) does not stem from improved fundamentals: the day brought a Nasdaq deficiency notice and a statement that management knew of no reason for the earlier decline. A 20.26% gain from a price near USD 0.13 is a small move in dollar terms and could easily reverse. The real question is whether the company cures the bid price shortfall by May 3, 2027, most likely through a reverse split. Further filings on its compliance plan, financing and United States thyroid launch are the next catalysts.






Please wait processing your request...